AstraZeneca Pharma India reported robust Q4 results with growth of 33 percent year-on-year, and a strong dividend payout.

Nikunj Parikh - Mumbai Bureau May 26, 2026 1,200 Views

AstraZeneca Pharma India Limited reported PAT of Rs 448.8 million and revenue from operations of Rs 5.79 billion for the March quarter FY26. During its May 26, 2026, board meeting, the pharmaceutical major announced a generous dividend of Rs 36 per equity share, indicating robust financial health and shareholder trust.

AstraZeneca Pharma India Limited (AZPIL) reported strong financial results for the fourth quarter of FY26, with a 33 percent increase in total revenue compared to the same period last year. The science-based biopharmaceutical company continues to expand its footprint in major therapeutic areas and provide innovative medicines to patients in India.

AstraZeneca Pharma India's revenue from operations for the quarter that ended March 31, 2026, stood at Rs 5.79 billion, up from Rs 4.80 billion in the same quarter last year. Profit after tax for the Q4 FY26 was Rs 448.8 million compared to Rs 582.5 million in Q4 FY25. Profit before exceptional items and tax was Rs 592.2 million for the quarter, demonstrating better operational efficiency.

Annual Results Show Continued Progress

The overall financial performance was outstanding during the full financial year FY26, as total revenue from operations increased to Rs 22.76 billion, a significant increase from Rs 17.16 billion in FY25. The annual profit after tax jumped to Rs 1.88 billion from Rs 1.16 billion in the last year, indicating good profitability improvement. The company maintained impressive earnings per share of Rs 75.01 for FY26 compared to Rs 46.30 in FY25.

Therapy-Wise Performance

The oncology segment was the top performer for the company, accounting for Rs 16.10 billion in revenue during FY26, reflecting robust demand for cancer therapeutics. The biopharmaceuticals portfolio, which includes cardiovascular, renal metabolism, respiratory and vaccine programs, made a contribution of Rs 5.24 billion. The rare disease segment, which saw substantial growth, accounted for Rs 214.6 million in revenues.

Shareholder Rewards and Corporate Governance

The board of directors has recommended a final dividend of Rs 36 per equity share (face value Rs 2) for FY26, which will be totalled up to Rs 900 million and will be put for approval at the upcoming annual general meeting of shareholders. The company also approved the reappointment of Shilpa Divekar Nirula as a Non-Executive Independent Director for another five-year term from December 29, 2026.

Regulatory Achievements and Pipeline Expansion

In FY26, AstraZeneca India gained 11 new regulatory approvals for medicines and indications from the Central Drugs Standard Control Organization, solidifying its position as a leader in each therapy area. Significant approvals include Durvalumab for multiple indications of cancer such as endometrial cancer, muscle invasive bladder cancer, gastric cancer and liver cancer, and Eculizumab for rare diseases, which is the first anti-complement therapy approved in India.

Key Highlights

The profit after tax for the quarter ended in FY26 Q4 was Rs 448.8 million.The Q4 FY26 PAT was Rs 448.8 million.
The revenue from operations for Q4 FY26 is projected to be Rs 5.79 billion.
The revenue from operations for the full year FY26 is Rs 22.76 billion, up 33 percent from the previous year.
Annual profit after tax rose to Rs 1.88 billion, from Rs 1.16 billion in FY25.
The company's earnings per share for the FY26 are Rs 75.01.
The final dividend recommended is Rs 36 per equity share, totaling Rs 900 million.
11 regulatory approvals obtained during FY26
Oncology segment revenue rose by 17.5% to Rs 16.10 billion.Oncology segment revenue grew by 17.5% to Rs 16.10 billion.
The revenue from biopharmaceuticals was Rs 5.24 billion.
Total assets of Rs 19.89 billion as of March 31, 2026